Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Hurwitz

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studiesHerbert I Hurwitz, Leonard B Saltz, Eric Van Cutsem, et al.
Journal of the American College of Surgeons|December 25, 2007
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastasesSrinevas K Reddy, Michael A Morse, Herbert I Hurwitz, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burdenEun L Langman, Paul V Suhocki, Herbert I Hurwitz, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 8, 2008
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective studySrinevas K Reddy, Gloria Broadwater, Donna Niedzwiecki, et al.
Clinical Colorectal Cancer|August 23, 2011
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancerNan Soon Wong, Nishan H Fernando, Johanna C Bendell, et al.
The Oncologist|March 15, 2013
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studiesHerbert I Hurwitz, Pamela S Douglas, John P Middleton, et al.
Cancer Medicine|May 2, 2013
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumabYingmiao Liu, Mark D Starr, Anuradha Bulusu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2018
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancerS Siena, A Sartore-Bianchi, S Marsoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Phase I trial of pazopanib in patients with advanced cancerHerbert I Hurwitz, Afshin Dowlati, Shermini Saini, et al.
British Journal of Cancer|November 30, 2018
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancerFotios Loupakis, Herbert I Hurwitz, Leonard Saltz, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studiesHerbert I Hurwitz, Leonard B Saltz, Eric Van Cutsem, et al.
Journal of the American College of Surgeons|December 25, 2007
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastasesSrinevas K Reddy, Michael A Morse, Herbert I Hurwitz, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burdenEun L Langman, Paul V Suhocki, Herbert I Hurwitz, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 8, 2008
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective studySrinevas K Reddy, Gloria Broadwater, Donna Niedzwiecki, et al.
Clinical Colorectal Cancer|August 23, 2011
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancerNan Soon Wong, Nishan H Fernando, Johanna C Bendell, et al.
The Oncologist|March 15, 2013
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studiesHerbert I Hurwitz, Pamela S Douglas, John P Middleton, et al.
Cancer Medicine|May 2, 2013
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumabYingmiao Liu, Mark D Starr, Anuradha Bulusu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2018
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancerS Siena, A Sartore-Bianchi, S Marsoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Phase I trial of pazopanib in patients with advanced cancerHerbert I Hurwitz, Afshin Dowlati, Shermini Saini, et al.
British Journal of Cancer|November 30, 2018
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancerFotios Loupakis, Herbert I Hurwitz, Leonard Saltz, et al.
Pageof 19